VKA
VKA is a pharmaceutical drug with 10 clinical trials. Currently 1 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
75.0%
6 of 8 finished
25.0%
2 ended early
1
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Anticoagulation in Patients With Venous Thromboembolism and Cancer
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial
Clinical Trials (10)
Anticoagulation in Patients With Venous Thromboembolism and Cancer
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
The Greek AntiPlatElet Atrial Fibrillation Registry.
Health-related Quality of Life in Patients on Anticoagulants
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10